Publikation
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Wissenschaftlicher Artikel/Review - 23.11.2015
Geyer Holly L, Scherber Robyn, Kosiorek Heidi, Dueck Amylou C, Kiladjian Jean-Jacques, Xiao Zhijian, Slot Stefanie, Zweegman Sonja, Sackmann Federico, Fuentes Ana Kerguelen, Hernández-Maraver Dolores, Döhner Konstanze, Harrison Claire N, Radia Deepti, Muxi Pablo, Besses Carlos, Cervantes Francisco, Johansson Peter L, Andreasson Bjorn, Rambaldi Alessandro, Barbui Tiziano, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Maldonado Norman, Barosi Giovanni, Ferrari Maria L, Gale Robert Peter, Birgegard Gunnar, Xu Zefeng, Zhang Yue, Sun Xiujuan, Xu Junqing, Zhang Peihong, te Boekhorst Peter A W, Commandeur Suzan, Schouten Harry, Pahl Heike L, Griesshammer Martin, Stegelmann Frank, Lehmann Thomas, Senyak Zhenya, Vannucchi Alessandro M, Passamonti Francesco, Samuelsson Jan, Mesa Ruben A
Bereiche
PubMed
DOI
Kontakt
Zitation
Art
Zeitschrift
Veröffentlichungsdatum
eISSN (Online)
Seiten
Kurzbeschreibung/Zielsetzung
Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients with PV patients who have a history of prior hydroxyurea (HU) use (including resistance or intolerance), phlebotomy requirements, and palpable splenomegaly. We aimed to determine how these features contribute alone and in aggregate to the PV symptom burden.